|Year : 2013 | Volume
| Issue : 1 | Page : 1-10
D2M-dopaminergic receptor and 5-HT3 serotoninergic receptor antagonists having antiemetic profile
Mohamed N. Aboul-Enein1, Aida A. EL-Azzouny1, Yousreya A. Maklad1, Mohamed I. Attia2, Mohamed Abd EL-Hamid Ismail3, Walaa H.A. Abd EL-Hamid4
1 Department of Medicinal and Pharmaceutical Chemistry, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt
2 Department of Medicinal and Pharmaceutical Chemistry, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
4 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr University for Science &Technology, 6th of October City, Egypt
|Date of Submission||15-Mar-2013|
|Date of Acceptance||11-Mar-2013|
|Date of Web Publication||18-Jul-2014|
Mohamed N. Aboul-Enein
Department of Medicinal and Pharmaceutical Chemistry, Pharmaceutical and Drug Industries Research Division, National Research Centre, 12622 Dokki, Giza, Egypt
Source of Support: None, Conflict of Interest: None
Metoclopramide is the prototype of the orthopramide family and is used clinically as a stimulant of upper gastrointestinal motility and as an antiemetic. Its antiemetic potential is attributed mainly to the antagonist activity at D2-dopaminergic receptors in the chemoreceptor trigger zone of the central nervous system. Besides, ondansetron was the first selective 5-HT3 serotoninergic receptor antagonist used in clinics as an antiemetic. Herein, the antiemetic profile of different chemical classes of D2-dopaminergic receptor and 5-HT3 serotoninergic receptor antagonists will be discussed, which may be helpful in the development of potent antiemetic agents.
Keywords: antagonists, antiemetic, D2-dopaminergic receptor, 5-HT3 serotoninergic receptor
|How to cite this article:|
Aboul-Enein MN, EL-Azzouny AA, Maklad YA, Attia MI, Abd EL-Hamid Ismail M, Abd EL-Hamid WH. D2M-dopaminergic receptor and 5-HT3 serotoninergic receptor antagonists having antiemetic profile. Egypt Pharmaceut J 2013;12:1-10
|How to cite this URL:|
Aboul-Enein MN, EL-Azzouny AA, Maklad YA, Attia MI, Abd EL-Hamid Ismail M, Abd EL-Hamid WH. D2M-dopaminergic receptor and 5-HT3 serotoninergic receptor antagonists having antiemetic profile. Egypt Pharmaceut J [serial online] 2013 [cited 2020 Mar 29];12:1-10. Available from: http://www.epj.eg.net/text.asp?2013/12/1/1/136938
| Introduction|| |
Vomiting is the forceful repulsion of the contents of one’s stomach through the mouth and sometimes the nose and it may result from many causes, ranging from gastritis or poisoning to brain tumor or elevated intracranial pressure. It is generally considered to be a protective mechanism by which undesirable substances are evacuated quickly from the gastrointestinal tract. Vomiting is different from regurgitation, although the two terms are often used interchangeably. Regurgitation is the return of undigested food back up the esophagus to the mouth, without the force and displeasure associated with vomiting. Nausea, which also has an impact on the gastrointestinal tract, is the sensation of discomfort in the upper stomach with the urge to vomit 1. Persistent nausea may lead to loss of appetite and reduction of food uptake until the point of malnutrition and debilitation. Gastrointestinal infections (37%) and food poisoning are the most common causes of nausea and vomiting besides side effects from medications (3%) and pregnancy 1,2. In 10% of people the cause remains unknown 2. Prolonged and severe vomiting leads to hypochloremia, hypokalemia, alkalosis, and dehydration; it can even cause death, especially in children. Therefore, treatment should be directed mainly toward eliminating the causes of illness. This review focuses on the antiemetic agents that potentially act as antagonists to the D2-dopaminergic and 5-HT3 serotoninergic receptors.
| Mechanism of emesis|| |
The act of emesis is very complicated and involves a series of coordinated activities and changes in the respiratory and gastrointestinal musculature. It is usually preceded by salivation, nausea, malaise, lassitude, weakness, retching movements, and characteristic postures of the head and body adopted to final expulsion of vomitus 3,4. This order of events indicates the existence of at least two central areas concerned with the vomiting act, namely, the chemoreceptor trigger zone (CTZ), which can be stimulated by chemical agents such as the dopaminergic apomorphine and transmits impulses to the vomiting centre itself, which is located in the reticular core of the medulla 2.
The latter center lies in proximity to the other centers such as inspiratory and expiratory centers, the vasomotor center, salivary nuclei, and vestibular nuclei. The action of all these centers may manifest as the act of vomiting 2. Impulses from all these centers pass through the CTZ to the vomiting center, resulting in emesis 5–7.
Sites other than the CTZ may be effective in the stimulation of emesis. Thus, visceral afferent impulses mediated through the parasympathetic and sympathetic routes transmit to the vomiting center impulses that result in the genesis of vomiting 8,9.
| Antiemetic agents|| |
Antiemetic agents are drugs that are used for the prophylaxis, control, and prevention of nausea and vomiting. Emesis is the main symptom for motion sickness, during the first trimester in pregnancy, in the case of hyperemesis gravidarum, and of radiation sickness resulting during the treatment of tumors by irradiation and using cytotoxic drugs. In addition, postoperative vomiting can also occur, which may be due to the use of general anesthetics and opiate analgesics after surgical operations. Gastrointestinal irritation because of peptic ulcer and ulcerative colitis also leads to nausea and vomiting. Antiemetics include various classes and groups of drugs with versatile pharmacological mechanisms.
The neurotransmitter dopamine plays an important role in neural functions involving reward processes, approach behavior, economic decision making, adaptive behavior, motion, and cognition 10. Dopamine receptors belong to two subclasses, with D1 and D5 receptors sharing homology and coupling with Gs and D2, D3, and D4 receptors coupling with Gi.
Selective D1-receptor antagonists have been studied as potential therapeutics for Parkinson’s disease, psychotic behavior, substance abuse, and obesity 11 in animal models and in human clinical trials 12.
D2-receptor antagonists were the first antiemetics used; these drugs are currently primarily used as rescue antiemetics. The primary reason for the ignorance of these drugs is frequent induction of extrapyramidal side effects such as akinesia, akathisia, and acute dystonic reactions. Domperidone 1 and metopimazine 2 are examples of D2-receptor antagonists that are effective against nausea, which is a more troublesome chemotherapy-induced side effect than vomiting; these do not cause extrapyramidal side effects [Figure 1] 13.
Phenothiazine was first synthesized by Bernthsen in 1883. In 1934 14, it was found to possess insecticidal properties. Later, Hardwood et al. 15 discovered the anthelmintic activity of this compound in swine ascaridosis. In 1946, Halpern and Ducrot 16 screened various phenothiazine compounds for antihistaminic properties. The first compound with definite therapeutic value was promethazine 3, which has proven antihistaminic as well as sedative and hypnotic properties 17.
In 1950, the first neuroleptic phenothiazine prototype, chlorpromazine 4, was introduced. It possesses a large number of pharmacological activities such as adrenolytic, antidopaminergic, antihistaminic, antiserotonin, antimuscarinic, and antiemetic properties 18–22. Subsequently, numerous phenothiazines have been introduced such as antiemetics with increased antiemetic potency, reduced cardiovascular effects, milder tranquilizing action, and decreased extrapyramidal side effects 23–25.
The difference in antiemetic activities between the neuroleptic phenothiazines is because of differences in the site of their sequestration in the central nervous system; however, they act predominantly on the CTZ.
Phenothiazines are classified into three groups according to the substituents on nitrogen: (i) aliphatic analogues, which bear acyclic groups; (ii) piperidines, which contain piperidine-derived groups; (iii) piperazine, which incorporate piperazine-derived substituents. The most relevant antiemetic phenothiazines (3–15) are illustrated in [Table 1].
Neuroleptic drugs like droperidol 16 and haloperidol 17 are major tranquillizing drugs, which possess significant antiemetic activity as a result of their D2-receptor antagonist properties, especially when administered through the intravenous and intramuscular routes 43. However, side effects 44,45 such as drowsiness, dysphoria, delayed discharge, extrapyramidal reactions, restlessness, and anxiety after discharge have led to the current reluctance to use these agents in the outpatient setting. The structures of the commonly used antiemetic butyrophenones are depicted in [Table 2].
Metoclopramide hydrochloride monohydrate (Primperan 21; [Table 3] is a benzamide derivative related to orthopramides class that belongs to the neuropsychotropic, antipsychotic neuroleptics [Table 3]. It is a derivative of procainamide but it is virtually devoid of antiarrhythmic or local anesthetic activity in clinical doses 67. It shows both central and peripheral antiemetic activities. It is rapidly absorbed orally but has a wide range of oral bioavailability. It has a plasma half life of 4–6 h. In addition to its ability to block dopaminergic receptors at the CTZ, metoclopramide increases lower esophageal sphincter tone and enhances gastric and small bowel motility, thereby preventing delayed gastric emptying caused by opioid analgesics 68. Although it is not effective in controlling motion sickness, metoclopramide has some peripheral cholinergic actions.
High doses of metoclopramide (1–2 mg/kg) are effective in managing chemotherapy-induced emesis 69; however, this is associated with high incidence of dystonic reactions and extrapyramidal side effects.
It has been successfully used to treat dyspepsia, gastrointestinal disorders, including irritable colon syndrome, and spastic constipation 67.
This gastroprokinetic activity is attributed to the release of acetylcholine upon stimulation of 5-HT4 receptors, whereas the antiemetic activity is attributed to the antagonistic activity at both 5-HT3 serotoninergic and D2-dopaminergic receptors in the CTZ of the central nervous system. In addition, it stimulates orthograde peristalsis, leading to suppression of the bile reflux, with subsequent promotion of healing of gastric ulcers and prevention of relapse. However, metoclopramide does not accelerate healing of duodenal ulcers 70.
The antiemetic activity of metoclopramide as an antiapomorphine drug is 35 times greater and more selective than that of chlorpromazine 71. Further, it shows no sedative action at its antiemetic doses 71. However, at large doses it produces extrapyramidal side effects. It exerts its antiemetic activity through central 72,73 and peripheral 74 dopamine receptor antagonism. Moreover, metoclopramide is ineffective against motion sickness and emesis occurring in labyrinthine episodes 71.
Orthopramides possess three common structural elements required for binding to the receptor site: an aromatic moiety, a carbonyl group or carbonyl group bioisosteres, and a basic nitrogen atom. The weak affinity and lack of selectivity of metoclopramide for dopaminergic and serotoninergic receptors can be explained by the large number of permissible conformers because of the flexibility of its amino chain. Accordingly, Aboul-Enein and colleagues 75,76 studied certain molecular modifications of metoclopramide, which imply (i) a change in the substituents of the aromatic ring, (ii) structural variations in the amine moiety, and (iii) an increase in the lipophilicity through a change in the vicinal carbon atom of the basic nitrogen to a cyclohexane ring (22–24; [Figure 2].
These compounds were evaluated for their dopamine D2-receptor antagonistic activity in vivo by measuring their ability to inhibit apomorphine-induced chewing “Zwansgnagen” in rats. Among these compound, 24 possessed an ED50 of 5.94 µmol/kg, being nearly two-fold more potent than the previously reported cyclohexane-based dopamine D2-receptor antagonist 23 (ED50=11.66 µmol/kg). Molecular simulation study of 24, including fitting to the three-dimensional model of dopamine D2-receptor antagonists using Discovery Studio 2.5 programs showed high-fit values 75. The experimental dopamine D2-receptor antagonistic activity was consistent with the findings of the molecular modeling study. Other substituted benzamides [Table 3] that have been evaluated as antiemetics include trimethobenzamide (25, Tigan), clebopride (27), cisapride (30), and alizapride (39) 77. Trimethobenzamide is an antiemetic having some structural similarities to both reserpine and antihistamines 78 as well as to orthopramides. It possesses one-tenth to one-twentieth of the antiemetic activity of chlorpromazine. Its antiemetic action is primarily on the CTZ. Trimethobenzamide does not cause depression at very high doses. It has no sedative, hypotensive, or extrapyramidal effects; moreover, it shows no antihistaminic activity, and it proved effective against vomiting from various causes 79,80.
Cisapride 30 has a greater ability than metoclopramide to reverse morphine-induced gastric stasis and is not associated with extrapyramidal side effects. However, cisapride does not prevent the decrease in lower esophageal tone following antagonism by neostigmine in the form of neuromuscular blockade and has lesser antiemetic activity than metoclopramide.
It is worth mentioning that metoclopramide and its congeners, besides being potent antiemetics, show neuroleptic, antidyskinetic, and antiulcer effects, also being useful as nonhormonal therapeutic agents in severe cases of menopausal disorders 67,81.
5-HT3 serotoninergic receptor antagonists
5-HT3 antagonists are a class of medications that act as receptor antagonists at the 5-HT3 receptor, a subtype of the serotonin receptors found at the terminal ends of the vagus nerve and in certain areas of the brain. They are used as antiemetics in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling nausea and vomiting caused by cancer chemotherapy and are considered the gold standard for this purpose 82.
5-HT3 receptors are present at several critical sites involved in emesis, including vagal afferents, the solitary tract nucleus, and the area postrema itself. Serotonin is released by the enterochromaffin cells of the small intestine in response to chemotherapeutic agents and may stimulate the vagal afferents (through the 5-HT3 receptor) to initiate the vomiting reflux. 5-HT3 receptor antagonists suppress vomiting and nausea by preventing serotonin from binding to the 5-HT3 receptors. The highest concentration of 5-HT3 receptors in the central nervous system is found in the solitary tract nucleus and CTZ, and 5-HT3 antagonists may also suppress vomiting and nausea by acting at these sites 59.
5-HT3 serotoninergic receptor
5-HT3 antagonists are most effective in prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), especially that caused by highly emetogenic drugs such as cisplatin. When used for prevention and treatment of CINV, they may be administered alone or, more frequently, in combination with a glucocorticoid, usually dexamethasone. They are usually administrated intravenously, shortly before administration of the chemotherapeutic agent 60, although some authors have argued that oral administration may be preferred 83. The concomitant administration of an NK1 receptor antagonist, such as aprepitant, significantly increases the efficacy of 5-HT3 antagonists in preventing both acute and delayed CINV 84.
5-HT3 antagonists are also indicated in the prevention and treatment of radiation-induced nausea and vomiting, when needed, and postoperative nausea and vomiting. Although they are highly effective at controlling CINV – they stop symptoms altogether in up to 70% of people and reduce them in the remaining 30% – they are only as effective as other agents in controlling postoperative nausea and vomiting.
Current evidence suggests that 5-HT3 antagonists are ineffective in controlling motion sickness 85. A randomized, placebo-controlled trial of ondansetron 40 to treat motion sickness in air ambulance personnel showed subjective improvement, but it was statistically insignificant.
Chemical structures of the first generation 5-HT3 receptor antagonists 86 can be categorized into three main classes [Table 4].
Ondansetron 40 was the first 5-HT3 antagonist; it was developed by Glaxo around 1984. Its efficacy was first established in 1987 in animal models 90. Several studies have demonstrated that ondansetron produces an antiemetic effect equal to or superior to that of high doses of metoclopramide; however, ondansetron has a superior toxicity profile compared with dopaminergic antagonist agents 88,91. Ondansetron (0.15 mg/kg) is administered intravenously 15–30 min before chemotherapy, and this dose is repeated every 4 h for two additional doses.
Ondansetron is not approved for use in children younger than 4 years. Its clearance is diminished in patients with severe hepatic insufficiency; therefore, such patients should receive a single injectable or oral dose no higher than 8 mg. The major adverse effects of ondansetron include headache, constipation or diarrhea, fatigue, dry mouth, and transient asymptomatic elevation in liver function tests (alanine and aspartate transaminases), which may be related to concurrent cisplatin administration.
Dolasetron 42 was first mentioned in the literature in 1989 92. Both oral and injectable formulations of dolasetron are administered for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses. Dolasetron should be administered intravenously or orally at 1.8 mg/kg as a single dose ∼30 min before chemotherapy 87.
Granisetron 41 was developed around 1988 93. It has demonstrated the same efficacy and safety margin as ondansetron in preventing and controlling nausea and vomiting at broad-range doses (e.g. 10–80 µg/kg and empirically 3 mg/dose) especially in patients receiving emetogenic chemotherapy, including a high dose of cisplatin 94.
Ramosetron 43 is only available in Japan and certain Southeast Asian countries as of 2008. It has a higher affinity for the 5-HT3 receptors than do the older 5-HT3 antagonists, and it maintains its effects over 2 days. It is therefore significantly more effective against delayed CINV 89. In animal studies, ramosetron was also effective against irritable bowel syndrome-like symptoms .
Palonosetron 44 is the newest 5-HT3 receptor antagonist. It shows antiemetic activity at both central and gastrointestinal sites. In comparison with the older 5-HT3 antagonists, it has a higher binding affinity to the 5-HT3 receptors, a higher potency, a significantly longer half life (∼40 h; four to five times longer than that of dolasetron, granisetron, or ondansetron), and an excellent safety profile. A dose finding study demonstrated that the effective dose was 0.25 mg or slightly higher 87.
| Conclusion|| |
Antiemetics include various classes and groups having versatile pharmacological mechanisms. This review deals with D2-dopaminergic receptor and 5-HT3 serotoninergic receptor antagonists possessing antiemetic potential, which could be considered as biocandidates in the development of new antiemetics or targets for extensive molecular modifications in order to accentuate some of their effects and attenuate or abolish side effects.
| References|| |
|1.||Metz A, Hebbard G. Nausea and vomiting in adults-a diagnostic approach. Aust Fam Physician. 2007;36:688–692 |
|2.||Britt H, Fahridin S. Presentations of nausea and vomiting. Aust Fam Physician. 2007;36:682 |
|3.||Wang SCRoot WS, Hofman FG. Physiological pharmacology. Emetic and antiemetic drugs. 1965;vol. II New York and London Academic Press:225–328 |
|4.||Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm. 2005;62:1247–1260 |
|5.||Seigel LJ, Longo DL. The control of chemotherapy induced emesis. Ann Intern Med. 1981;95:352–359 |
|6.||Marty M. Future trends in cancer treatment and emesis control. Oncology. 1993;50:159–162 |
|7.||Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient. J Am Med Assoc. 1981;245:293–296 |
|8.||Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5:192–230 |
|9.||Nasrallah HA, Brecher M, Paulsson B. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disord. 2006;8(5 Pt 1):467–474 |
|10.||Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci. 2007;30:259–288 |
|11.||Olver JS, O’Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, et al. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder. J Affect Disord. 2009;114:321–326 |
|12.||Haney M, Ward AS, Foltin RW, Fischman MW. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology (Berl). 2001;155:330–337 |
|13.||Herrstedt J, Sigsgaard T, Handberg J, Schousboe BM, Hansen M, Dombernowsky P. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol. 1997;15:1690–1696 |
|14.||Campbell FL, Sullivan WN, Smith LE, Haller HL. Insecticidal tests of synthetic organic compounds, chiefly tests of sulfur compounds against culicine mosquito larvae. J Econ Entomol. 1934;27:1176–1185 |
|15.||Harwood PD, Habermann RT, Roberts EH, Hunt WH. Preliminary observations on the effectiveness of crude, unconditioned phenothiazine for the removal of worms from horses. Proc Helm Soc Washington. 1940;7:18–20 |
|16.||Halpern BN, Ducrot R. Experimental research on a novel series of powerful antihistamines: thiodiphenylamine derivatives. Comp Rend Soc Bio. 1946;140:361–364 |
|17.||Tarkkila P, Torn K, Tuominen M, Lindgren L. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol Scand. 1995;39:983–986 |
|18.||Schenker E, Herbst H. Progress in drug research. Progrès des recherches pharmaceutiques. 1963;42:269–627 |
|19.||Girault J, Greengard P. The neurobiology of dopamine signaling. Arch Neurol. 2004;61:641–644 |
|20.||Courvoiries S, Fournel J, Ducrot R, Kolsky M, Koetschet P. Pharmacodynamic properties of 3-chloro-10-(3-dimethylaminopropyl)-phenothiazine hydrochloride; experimental study of a new substance used in potentialized anesthesia and in artificial hibernation. Arch Int Pharmacodyn Ther. 1953;92:305–361 |
|21.||Holzbauer M, Vogt M. The action of chlorpromazine on diencephalic sympathetic activity and on the release of adrenocorticotropic hormone. Br J Pharmacol Chemother. 1954;9:402–407 |
|22.||Hudson RD. Effects of Chlorpromazine on motor reflexes of the chronic spinal cat. Arch Int Pharmacodyn Ther. 1968;174:442–450 |
|23.||Piala JJ, High JP, Hassert GLJ, Burke JC, Craver BN. Pharmacological and acute toxicological comparisons of triflupromazine and chlorpromazine. J Pharmacol Exp Therap. 1959;127:55–65 |
|24.||Laffan RJ, Papandrianos DP, Burke JC, Craver BN. Antiemetic action of fluphenazine (Prolixin): acomparison with other phenothiazines. J Pharmacol Exp Ther. 1961;131:130–134 |
|25.||Bhargava KP, Candra OM. Antiemetic activity of phenothiazine in relation to their chemical structure. Br J Pharmacol Chemother. 1963;21:436–440 |
|26.||Couvoisier S, Ducrot R, Julov L, Leau O. General pharmacological properties of a new phenothiazine derivatives with powerful antihistaminic and antiallergic activity, 9,9-dioxo-10-(3-dimethylamino-2-methylpropyl)-phenothiazine. Arch Int Pharmacodyn Ther. 1962;135:364–375 |
|27.||Jo S-H, Hong H-K, Chong SH, Lee HS, Choe H. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel. Pharmacol Res. 2009;60:429–437 |
|28.||Delay J, Deniker P, Harl JM. Therapeutic psychiatric use of a selective centrally acting phenothiazine. Ann Med Psychol (Paris). 1952;110:112–117 |
|29.||Charpentier P. Phenothiazine derivatives. 1953 US 2645640 |
|30.||Wirth W. The pharmacological action of promazine. Arzneimittelforschung. 1958;8:507–511 |
|31.||Yale HL, Sowinski F, Bernstein J. 10-(3-dimethylaminopropyl)-2-(trifluromethyl)-phenothiazine hydrochloride (Vesprin) and related compounds. J Am Chem Soc. 1957;79:4375–4379 |
|32.||Feldmann PE. An analysis of the efficacy of diazepam. J Neuropsychiat. 1962;3(Suppl 1):62–67 |
|33.||Dobkin AB, Purkin N. The antisialogugue effect of phenpthiazine derivatives: comparison of precazine, perphenazine, fluphenazine, thiopropazate, pipamazine and triflupromazine. Br J Anaesth. 1960;32:57–59 |
|34.||Bowes HA. Ataractic composition comprising 10-(1-methyl-3-piperidylmethyl)-phenothiazine and 10-(3-dimethyl-amino-propyl)-2-chlorophenothiazine. 1959 US 2872376 |
|35.||Jacob RM, Robert JG. Process for the preparation of phenthiazine derivatives. 1960 DE 1092476 |
|36.||Goldenthal EIA. Compilation of LD50 values in new born and adult animals. Toxicol Appl Pharmacol. 1971;18:185–207 |
|37.||Tedeschi DH, Tedeschi RE, Fellows EJ. The effects of tryptamine on the central nervous system, including a pharmacological procedures for the evaluation of iproniazid-like drugs. J Pharmacol Exp Ther. 1959;126:223–232 |
|38.||Bourquin JP, Schward G, Gamboni G, Fischer R, Ruesch L, Theuss E, et al. Synthses in the phenothiazine area - Part 1 Mercaptophenothiazine derivatives. J Helv Chim Acta. 1958;41:1061–1072 |
|39.||Hotovy R, Kapff-Walter J. The pharmacological properties of perphenazine sulphoxide. Arzneimittelforschung. 1960;10:638–650 |
|40.||Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17:2971–2994 |
|41.||Kline NS, Simpson GM. A long acting phenothiazine in office practice. Am J Psychiatry. 1964;120:1012–1014 |
|42.||Toldy L, Toth L, Fekete M, Borsy J. Phenothiazine derivatives. Acta Chim Acad Sci Hung. 1965;44:301–325 |
|43.||Loeser EA, Bennet EA, Stanley TH, Machin R. Comparison of droperidol, haloperidol and prochlorperazine as postoperative antiemetic. Can Anaesth Soc J. 2007;26:125–127 |
|44.||Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anaesth Analg. 1979;58:396–400 |
|45.||Madej TH, Simpson KH. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases. Br J Anaesth. 1986;58:879–883 |
|46.||Bobon J, Collard J, Lecoq R. Benperidol and promazine: a “double blind” comparative study in mental geriatrics. Acta Neurol Belg. 1963;63:839–843 |
|47.||Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 1999;88:1370–1379 |
|48.||Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17:137–140 |
|49.||Nakra BR, Jones CJ, Majumdar AK, Gaind R. Preliminary evaluation of a new psychotropic drug, lenperone, in the treatment of acute schizophrenia. Curr Med Res Opin. 1977;4:529–534 |
|50.||Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry. 2003;36:3–6 |
|51.||. Report of the Second Public Health Service AIDS Prevention and Control Conference. Public Health Rep. 1988;103(Suppl 1):52–57 |
|52.||Fontaine J, Reuse JJ. Comparative study on the action of some substituted benzamides on the isolated ileum of the guinea pig. Arch Int Pharmacodyn Ther. 1975;213:322–327 |
|53.||Cuena Boy R, Macia Martinez MA. Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System. Aten Primaria. 1998;21:289–295 |
|54.||Bulteau G, Acher J. On the preparation of 2-alkoxy-4,5-substituted benzamides. 1973 DE 2327192 |
|55.||Lunsford CD, Cale AD. N-(4-Pyrazolidinyl) benzamides and their salts in pharmaceutical formulation. 1973 DE 2836062 |
|56.||Van Daele G. Novel N-(3-hydroxy-4-piperidinyl) benzamide. 1983 EP76530 |
|57.||Cooke HJ, Carey HV. The effects of cisapride on serotonin-evoked mucosal responses in guinea-pig ileum. Eur J Pharmacol. 1984;98:147–148 |
|58.||Brunton LL, Lazo J, Paker K Goddman & Gilman's the pharmacological basis of therapeutics. 2006 New York Mc Graw-Hill:1000–1003 |
|59.||Herrstedt J, Aapro MS, Rolia F, Kataja VV. ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol. 2005;16:i77–i79 |
|60.||Laville C, Margarit J. The influence of sulpiride on motor activity and vigilance in the mouse. Pathol Biol. 1968;16:663–665 |
|61.||Bruguerolle B, Jadot G, Valli M, Bouyard L, Fabregou-Bergier P, Perrot J, et al. Four benzamides (metoclopramide, sulpiride, sultopride and tiapride) effects on the oestrus cycle of the female rat: a comparative statistical study (author’s transl). J Pharmacol. 1981;12:27–36 |
|62.||Florvall LG, Oegren SO. 2,6-Dialkoxybenzamides, process for their preparation, composition and these compounds for use in treatment of psychotic disorders. 1979:EP831 |
|63.||Florvall GL, Lundstroem JOG, Raemsby SI, Oegren SO. Benzamido-Derivative. 1982 EP60235 |
|64.||Kohler C, Hall H, Ogren SO, Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D2 -receptors in the rat brain. Biochem Pharmacol. 1985;34:2251–2259 |
|65.||Thominet M, Acher J, Monier JC. Heterocyclic substituted benzamides and the process of their production. 1979 DE2901170 |
|66.||Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22:316–320 |
|67.||Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC, et al. Metoclopramide. An updated review of it’s pharmacological properties and clinical use. Drugs. 1983;12:81–131 |
|68.||Rowbotham DJ. Current management of postoperative nausea and vomiting. Br J Anaesth. 1992;69:46S–59S |
|69.||Steward DJ. Cancer therapy, vomiting and antiemetics. Can J Physiol Pharmacol. 1990;68:304–313 |
|70.||Goodman LS, Gilman A The pharmacological basis of therapeutics. 1980 New York Macmillan Publishing:997–1003 |
|71.||Bowman WC, Rand MJ Textbook of pharmacology. 19802nd ed. London Blackwell Scientific Publications:25.9 |
|72.||Pinnock RD, Ruff GHW, Turnbull MJ. Sulpiride blocks the action of dopamine in the rat substantia nigra. Eur J Pharmacol. 1979;56:413–414 |
|73.||Alander T, Anden NE, Grabowska-Anden M. Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1980;312:145–150 |
|74.||Hadley MS, King FD, McRitchie B, Turner DH, Watts EA. Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents. J Med Chem. 1985;28:1843–1847 |
|75.||Aboul-Enein MN, EL-Azzouny AA, Abdallah NA, Hegazy AY, Ebeid MY. Synthesis and antiemetic profile of certain N-[1-[(diethylamino)methyl]cyclohexyl] amides. Sci Pharm. 1990;58:273–280 |
|76.||Aboul-Enein MN, EL-Azzouny AA, Attia MI, Maklad YA, Abd El-Hamid Ismail M, Ismail NMS, Abd El-Hamid WHA. Dopamine D2 receptor antagonist activity and molecular modeling of certain new cyclohexane derived arylcarboxamides structurally related to metoclopramide. Dig J Nanomater Bios. 2012;7:537–553 |
|77.||Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77:162–184 |
|78.||Goldberg MW, Teitel S. Benzylamine derivatives. 1959 US 2879293 |
|79.||Schallek W, Heise GA, Keith EF, Bagdon RE. Anti-emetic activity of 4-(2-dimethylaminoethoxy)-N-(3,4,5-trimethoxybenzoyl)-benzylamine hydrochloride. J Pharmacol Exp Ther. 1959;126:270–277 |
|80.||Kolodny ALA. Controlled study of trimethobenzamide (Tigan), a specific antiemetic. Am J Med Sci. 1960;239:682–689 |
|81.||Van de Waterbeemd H, Carrupt PA, Testa B. Molecular electrostatic potential of orthopramides: implications for their interaction with the D2 dopamine receptor. J Med Chem. 1986;29:600–606 |
|82.||De Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother Pharmacol. 2005;56:231–238 |
|83.||Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm. 2000;57:1685–1697 |
|84.||Rolia F, Fatigoni S. New antiemetic drugs. Ann Oncol. 2006;17:ii96–ii100 |
|85.||Stott JR, Barnes GR, Wright RJ, Ruddock CJ. The effect on motion sickness and oculomotor function of GR 38032 F, A 5-HT3 receptor antagonist with antiemetic properties. Br J Clin Pharmacol. 1989;27:147–157 |
|86.||Gan TJ. Selective serotonine-5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19:225–238 |
|87.||Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994;74:1945–1952 |
|88.||Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991;9:721–728 |
|89.||Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc). 2002;38:75–89 |
|90.||Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB, et al. Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol. 1987;138:303–305 |
|91.||Kaasa S, Kvaloy S, Dicato MA, Ries F, Huys JV, Royer E, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer. 1990;26:311–314 |
|92.||Cassidy J, Raina V, Lewis C, Adams L, Soukop M, Rapeport WG, et al. Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. Br J Cancer. 1988;58:651–653 |
|93.||Sorensen SM, Humphreys TM, Palfreyman MG. Effect of acute and chronic MDL 73,147 EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol. 1989;163:115–118 |
|94.||Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer. 1996;32A:1523–1529 |
|95.||Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology. 2007;15:5–9 |
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]